Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30


Cancer statistics, 2003.

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ.

CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26.


Squalene epoxidase as hypocholesterolemic drug target revisited.

Chugh A, Ray A, Gupta JB.

Prog Lipid Res. 2003 Jan;42(1):37-50. Review.


The program of androgen-responsive genes in neoplastic prostate epithelium.

Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11890-5. Epub 2002 Aug 16.


Transcriptional programs activated by exposure of human prostate cancer cells to androgen.

DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD.

Genome Biol. 2002 Jun 14;3(7):RESEARCH0032. Epub 2002 Jun 14.


Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease.

LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL.

Cancer Res. 2002 Aug 1;62(15):4499-506.


The development of androgen-independent prostate cancer.

Feldman BJ, Feldman D.

Nat Rev Cancer. 2001 Oct;1(1):34-45. Review.


Gene expression profiling of the human prostate androgen response program.

Moore SM, Nelson PS.

J Androl. 2002 Mar-Apr;23(2):163-9. Review. No abstract available.


Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.

Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ.

Cancer Res. 2002 Feb 15;62(4):1008-13.


Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling.

Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP.

Oncogene. 2001 Oct 11;20(46):6718-23.


Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.

Yamada KM, Araki M.

J Cell Sci. 2001 Jul;114(Pt 13):2375-82. Review.


Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.

Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA, Ladanyi M.

Am J Pathol. 2001 Jul;159(1):179-92.


A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM.

Cancer Res. 2001 Jun 1;61(11):4315-9.


Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer.

Barry MJ.

N Engl J Med. 2001 May 3;344(18):1373-7. Review. No abstract available.


Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T.

Cancer Res. 2001 May 1;61(9):3550-5.


Interleukin-6 and prostate cancer progression.

Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET.

Cytokine Growth Factor Rev. 2001 Mar;12(1):33-40. Review.


Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM.

Cancer Res. 2001 Apr 1;61(7):2892-8.


Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes.

Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, McLeod DG, Moul JW, Srivastava S.

Int J Cancer. 2001 May 1;92(3):322-8.


Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.

Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM.

Cancer Res. 2000 Nov 1;60(21):6134-41.


Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T.

J Urol. 2000 Dec;164(6):1992-5.


Molecular genetics of prostate cancer.

Abate-Shen C, Shen MM.

Genes Dev. 2000 Oct 1;14(19):2410-34. Review. No abstract available.

Supplemental Content

Support Center